{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:03:27Z","timestamp":1784847807650,"version":"3.55.0"},"reference-count":42,"publisher":"Korean Pediatric Society","issue":"9","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["e-cep.org"],"crossmark-restriction":true},"short-container-title":["Clin Exp Pediatr"],"published-print":{"date-parts":[[2025,9,15]]},"abstract":"<jats:p>Background: Allogeneic stem cell transplantation (allo-SCT) and chimeric antigen receptor (CAR) T-cell therapy offer potential complementary benefits.Purpose: This study aimed to ascertain whether incorporating consolidative allo-SCT after CAR T-cell therapy can augment the therapeutic outcomes of child and young adult patients with relapsed\/refractory hematologic malignancy.Methods: A comprehensive literature search of PubMed, ScienceDirect, Cochrane Library, EBSCOHost, ProQuest, and the grey literature repositories was performed for articles published between May 5, 2014, and May 5, 2024. We included studies reporting consolidative allo-SCT following CAR T-cell therapy for treating hematologic malignancies in subjects aged \u226425 years old. The outcomes of interest were complete remission, survival, relapse, and mortality rates. The estimates were pooled using random-effects meta-analysis. The risk of bias was evaluated using the Newcastle-Ottawa Scale, while the certainty of evidence was assessed using GRADE. This study follows the PRISMA 2020 criteria and is registered in the PROSPERO database (CRD42023433417).Results: Twelve cohort studies involving 380 patients, primarily those with B-cell acute lymphoblastic leukemia (B-ALL), were included. The CAR T-cell+SCT group showed a trend toward higher complete remission (odds ratio [OR], 2.74; 95% confidence interval [CI], 0.88\u20138.54; P= 0.08; I2=57%; evidence, very low); lower mortality (OR, 0.58; 95% CI, 0.27\u20131.27; P=0.17; I2=0%; evidence, low), and decreased relapse (OR, 0.18; 95% CI, 0.06\u20130.56; P=0.003; I2=41%; evidence, low) rates than those who did not proceed to SCT. In addition, both overall survival and leukemia-free survival rates showed a favorable trend toward the CAR T-cell+SCT group, respectively (hazard ratio, 0.44; 95% CI, 0.25\u20130.77; P=0.005; I2=0%; evidence, low; and hazard ratio, 0.29; 95% CI, 0.17\u20130.49; P&lt;0.00001; I2=0%; evidence, low). Common posttransplant toxicities include mild to moderate acute and chronic graft-versus-host diseases.Conclusion: Although the current level of evidence remains low or very low, allo-SCT following CAR T-cell infusion potentially benefits patient survival. Further clinical studies are required to confirm these findings.<\/jats:p>","DOI":"10.3345\/cep.2025.00031","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T02:01:06Z","timestamp":1751594466000},"page":"712-721","update-policy":"https:\/\/doi.org\/10.3345\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic stem-cell transplantation following chimeric antigen receptor T-cell therapy for treatment of relapsed\/refractory hematologic malignancy in children and young adults: a systematic review and meta-analysis"],"prefix":"10.3345","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3436-0624","authenticated-orcid":true,"given":"Ghea","family":"Mangkuliguna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8574-4255","authenticated-orcid":true,"given":"Edi Setiawan","family":"Tehuteru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5005-4707","authenticated-orcid":true,"given":"Reganedgary","family":"Jonlean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7163-3102","authenticated-orcid":true,"given":"Nicholas","family":"Adrianto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6932-2556","authenticated-orcid":true,"given":"Stella","family":"Kallista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1897","reference":[{"key":"ref1","first-page":"1211","volume-title":"The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017","author":"Force","year":"2019"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0164-6"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.784024"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25353"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61403-3"},{"key":"ref6","first-page":"439","volume-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","author":"Maude","year":"2018"},{"key":"ref7","first-page":"191","volume-title":"CAR-T therapy as a curative option for childhood acute lymphoblastic leukaemia (ALL) in developing countries [abstract]?","author":"Lim","year":"2020"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2011-301419"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915590"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001641"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.11.011"},{"key":"ref12","first-page":"E162","volume-title":"Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed\/refractory pediatric acute lymphoblastic leukemia","author":"Wang","year":"2021"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01703-0"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02262"},{"key":"ref15","first-page":"66","volume-title":"Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r\/r ALL through a national access scheme","author":"Espuelas","year":"2024"},{"key":"ref16","first-page":"21","volume-title":"Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage","author":"Summers","year":"2022"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007423"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02829-9"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/frhem.2023.1151744"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.1205"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"ref23","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]","author":"Wells"},{"key":"ref24","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023) [Internet]","author":"Higgins"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"ref27","volume-title":""},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39500.677199.ae"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01236-y"},{"key":"ref30","first-page":"177ra38","volume-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","author":"Brentjens","year":"2013"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27519"},{"key":"ref32","first-page":"1113882","volume-title":"The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies","author":"Sorkhabi","year":"2023"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400044"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.10.011"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1365"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611710"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1048296"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00247-8"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.605766"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.12659\/msm.890496"}],"container-title":["Clinical and Experimental Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-cep.org\/upload\/pdf\/cep-2025-00031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cep.org\/journal\/view.php?doi=10.3345\/cep.2025.00031","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cep.org\/upload\/pdf\/cep-2025-00031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T23:46:50Z","timestamp":1756770410000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-cep.org\/journal\/view.php?doi=10.3345\/cep.2025.00031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"URL":"https:\/\/doi.org\/10.3345\/cep.2025.00031","relation":{},"ISSN":["2713-4148"],"issn-type":[{"value":"2713-4148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"2025-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-04","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}